Benjamin Hickey
President chez RAYZEBIO, INC.
Fortune : 38 934 $ au 30/04/2024
Profil
Benjamin Joseph Hickey's current jobs include being a Director at Bristol-Myers Squibb Holdings 2002 Ltd., an Independent Director at Mural Oncology Plc, and the President of Rayzebio, Inc. His former jobs include being an Independent Director at Surface Oncology, Inc., a Director at Bristol-Myers Squibb Pharmaceuticals Ltd., the Chief Commercial Officer & Senior Vice President at Halozyme Therapeutics, Inc., and the Chief Commercial Officer at Mirati Therapeutics, Inc. Mr. Hickey obtained his undergraduate degree and an MBA from St. John's University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/03/2024 | 871 ( 0,00% ) | 38 934 $ | 30/04/2024 | |
-.--% | 01/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Benjamin Hickey
| Sociétés | Poste | Début |
|---|---|---|
| RAYZEBIO, INC. | President | 26/02/2024 |
Bristol-Myers Squibb Holdings 2002 Ltd.
 Bristol-Myers Squibb Holdings 2002 Ltd. Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings 2002 Ltd. is a holding British company that operates subsidiaries distributing and selling pharmaceutical products. The company is based in Uxbridge, UK. | Directeur/Membre du Conseil | 01/08/2016 |
Anciens postes connus de Benjamin Hickey
| Sociétés | Poste | Fin |
|---|---|---|
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 23/01/2024 |
| SURFACE ONCOLOGY, INC. | Directeur/Membre du Conseil | 08/09/2023 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2020 |
Bristol-Myers Squibb Pharmaceuticals Ltd.
 Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Directeur/Membre du Conseil | 03/09/2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Sales & Marketing | 01/08/2016 |
Formation de Benjamin Hickey
| St. John's University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 4 |
|---|---|
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Health Technology |
Bristol-Myers Squibb Holdings 2002 Ltd.
Bristol-Myers Squibb Holdings 2002 Ltd. Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings 2002 Ltd. is a holding British company that operates subsidiaries distributing and selling pharmaceutical products. The company is based in Uxbridge, UK. | Distribution Services |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
